LONDON: Syncona Ltd, a leading life science investor, announced Monday that its portfolio company, Achilles Therapeutics plc, has recommended a members’ solvent voluntary liquidation to return capital to shareholders. The decision follows a review by the Achilles Board, which determined the move to be in the best interests of the company and its shareholders. Achilles…